batimastat

Batimastat is a synthetic small molecule that acts as a broad-spectrum inhibitor of matrix metalloproteinases (MMPs), enzymes involved in the breakdown of extracellular matrix components. By inhibiting MMPs, batimastat exhibits antineoplastic and antiangiogenic activity, making it an angiogenesis inhibitor and antimetastatic agent. It was developed by British Biotech (now Vernalis) and was the first MMP inhibitor to enter clinical trials for cancer treatment. Batimastat reached Phase III clinical trials but was never marketed due to administration challenges; it cannot be given orally and intraperitoneal injection led to complications such as peritonitis. Its mechanism involves mimicking natural MMPI peptides, competitively binding to the active site of MMPs via its peptide backbone and hydroxamic acid group[1][2][3][4][5].